Compare GTY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | NUVB |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1998 | N/A |
| Metric | GTY | NUVB |
|---|---|---|
| Price | $36.09 | $5.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $32.60 | $11.38 |
| AVG Volume (30 Days) | 533.0K | ★ 9.1M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $221,727,000.00 | N/A |
| Revenue This Year | $9.39 | $203.82 |
| Revenue Next Year | $7.83 | $58.18 |
| P/E Ratio | $83.93 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $25.39 | $2.18 |
| 52 Week High | $36.12 | $9.75 |
| Indicator | GTY | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 73.33 | 54.31 |
| Support Level | $32.41 | $5.26 |
| Resistance Level | N/A | $6.37 |
| Average True Range (ATR) | 0.58 | 0.36 |
| MACD | 0.18 | -0.04 |
| Stochastic Oscillator | 87.54 | 47.09 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.